Tango Therapeutics to stop development of cancer therapy
May 23 (Reuters) - Tango Therapeutics TNGX.O said on Thursday it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,